Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges
The pharmaceutical industry is increasingly exploring oral delivery as an alternative to injections for peptides, proteins, oligonucleotides, and other complex molecules—but significant formulation and biological barriers remain.
In this Drug Development & Delivery Expert Insights interview, Cindy Dubin speaks with Dr. Anil Kane, Global Head of Technical and Scientific Affairs at Patheon, part of Thermo Fisher Scientific, about the science driving advances in oral peptide drug delivery.
Dr. Kane explains why oral peptides are attracting increased investment and examines the challenges developers must overcome, including enzymatic degradation, acid instability, poor epithelial permeability, low bioavailability, PK variability, and food effects.
The discussion also explores emerging formulation approaches, including absorption and permeation enhancers, functional coatings, targeted-release systems, mucoadhesive tablets, lipid-based delivery, and multiparticulate systems. Dr. Kane also addresses the need for improved in vitro screening and predictive models that could help developers evaluate formulations earlier, accelerate development, and reduce reliance on costly downstream studies.
Watch the full Expert Insights interview to discover the technologies, expertise, and development strategies that could help advance the next generation of orally delivered peptide therapeutics.
Learn more about Thermo Fisher’s CDMO services for oral solid dose.
Posted Date: 9/17/2026
This record has been viewed 95 times.
